ArticleWorld journal of surgical oncology2026
ZP3 promotes hepatocellular carcinoma progression via the Notch signaling pathway and is associated with the tumor microenvironment and immunotherapy response.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundZona pellucida glycoprotein 3 (ZP3) is an important member of the zona pellucida glycoprotein family. However, the underlying mechanisms and immune regulation in hepatocellular carcinoma (HCC) remain unclear.
methodsThe protein expression level of ZP3 in HCC tissues was detected via Western blotting (WB) and immunohistochemistry (IHC). The impact of ZP3 on tumor microenvironment (TME) modulation in HCC was analyzed via the TCGA database, and its potential for immunotherapy response was assessed via the Tumor Immune Dysfunction and Exclusion (TIDE) database. Lentivirus-mediated knockdown and overexpression of ZP3 were performed in HCC cell lines, both in vitro and in vivo via various techniques, including immunofluorescence (IF), EdU, wound healing, colony formation, migration, transcriptome sequencing, flow cytometry, and xenograft assays.
resultsWe confirmed that ZP3 protein levels were significantly greater in HCC tissues than in normal tissues through WB and IHC analyses. Functionally, ZP3 knockdown in Huh7 cells reduced proliferation, migration, and invasion and slowed tumor growth in xenograft models; conversely, ZP3 overexpression in LM3 cells intensified these oncogenic traits. Mechanistically, enrichment analysis of the transcriptome data suggested that ZP3 might promote HCC progression via the Notch signaling pathway. Furthermore, ZP3 knockdown decreased key components of the Notch pathway (Jagged1, Notch1, NICD1, and Hes1), whereas ZP3 overexpression activated this pathway. ZP3 expression was significantly correlated with tumor-infiltrating immune cells (such as M0 macrophages, T cells, and NK cells) and TME scores in HCC. Notably, patients with high ZP3 levels presented lower TIDE scores, indicating reduced immune evasion potential and a better response to immunotherapy.
conclusionZP3 promotes HCC progression by activating the Notch pathway and modulating the TME, highlighting its potential as both a prognostic biomarker and a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.